Neu Apparel Australia, Where Do Cats Go When They Die, Branded Disposable Coffee Cups, Mozart Symphony 41 Best Recording, Psu Umass Amherst, How To Hang A Flag On A Wall Without Nails, Vrqa Child Safe Standards, " />

qiagen news release

qiagen news release

QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). At QIAGEN we work tirelessly on novel approaches to support healthcare workers and scientists in their fight against COVID-19. The amended business combination agreement has been terminated due to the acceptance threshold not having been met. A total of 47% of the outstanding QIAGEN shares were tendered into the offer of EUR 43.00 per share at the expiry of the Acceptance Period on Monday, August 10, 2020, at Midnight Frankfurt time / 18:00 New York time. QIAGEN releases QIAstat-Dx test kit to the U.S. as first syndromic test for detection of SARS-CoV-2 coronavirus under new FDA policy As of June 30, 2020, QIAGEN employed more than 5,200 people in over 35 locations worldwide. Further information can be found at, Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Get the latest Qiagen N.V. (QGEN) stock news and headlines to help you in your trading and investing decisions. Stay up-to-date with our latest … Visit the QIAGEN Virtual Deep Dive microsite, QIAGEN reports results for third quarter 2020, QIAGEN plans to resubmit EUA submission in the U.S. for QIAreach SARS CoV-2 Antigen Test in the first quarter of 2021, QIAGEN confirms effectiveness of its SARS-CoV-2 PCR tests in the face of mutations of the coronavirus, QIAGEN Announces Global Distribution Agreement for the COSMIC Database from the Wellcome Sanger Institute, QIAGEN announces appointment of new Supervisory Board member, QIAGEN launches portable digital SARS-CoV-2 antigen test that can accurately analyze over 30 samples per hour, QIAGEN announces start of share repurchase for up to $100 million, QIAGEN launches NeuMoDx multiplex test to complete range of SARS-CoV-2 testing solutions in Europe and other markets, QIAGEN collaborates with BioNTech on companion diagnostics development for HPV-associated squamous cell carcinoma of the head and neck, QIAGEN to launch QuantiFERON SARS-CoV-2 for research into causes, spread and control of COVID-19 through T-cell response, QIAGEN increases outlook for 2020 and 2021. DGAP Voting Rights Announcement: QIAGEN N.V. QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 2021-01-08 / 22:05 Dissemination of a Voting Rights Announcement transmitted by DGAP - a … PetaGene, AstraZeneca, QIAGEN, and More: News From October 2019 October 31, 2019. QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it plans to resubmit in the first quarter of 2021 its QIAreach SARS-CoV-2 Antigen Test to the U.S. Food and Drug Administration for Emergency Use Authorization to detect SARS-CoV-2 antigens in people with active infections in 15 … Companies in the life sciences … Latest news on QIAGEN’s COVID-19 efforts. Dr. Haag was chosen as part of an … In addition, Thermo Fisher’s tender offer statement and other documents filed with the SEC are available at https://ir.thermofisher.com/investors. 27 WPÜG AND POSITION STATEMENT (. QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 2021-01-08 / 22:05 QIAGEN has filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC with respect to the tender offer on May 18, 2020, as amended from time to time; in addition, QIAGEN has published a document combining the recommendation statement pursuant to Sec. A latest round of assessments conducted in January 2021 again confirmed that no recorded mutations affected the sensitivity of QIAGEN assays for detection of SARS-CoV-2. READ MORE. VENLO, The Netherlands--(BUSINESS WIRE)-- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that Dr. Toralf Haag has been appointed a member of the Supervisory Board with immediate effect.He will also become a member of the Audit Committee. ... QIAGEN N.V. : Release of a capital market information. As we focus on greater value creation, QIAGEN builds on a disciplined capital allocation policy anchored by a healthy balance sheet to support investments into our business along with a commitment to increasing returns to shareholders.”. QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 2021-01-19 / 22:02 Show Press Release. Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 21.12.20 QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). The issuer is solely responsible for the content of this … To the extent that any of the statements contained herein relating to QIAGEN's outlook, products, launches, pipeline, regulatory submissions, collaborations, markets, strategy, employees, taxes or operating results; QIAGEN’s plans to continue its growth strategy and the execution of its strategy; QIAGEN’s commitment to support the global response to the COVID-19 pandemic; QIAGEN’s ability to address molecular testing needs in the life sciences and molecular diagnostics; the magnitude and duration of the COVID-19 pandemic; QIAGEN’s ability to increase its value through its growth strategy and initiatives; QIAGEN’s commercial initiatives, including initiatives to support the global response to the COVID-19 pandemic, to strengthen its leadership in sample technologies, to further its leadership in tuberculosis detection, to accelerate commercialization of the QIAstat-Dx and NeuMoDx systems, and to enter the digital PCR market with the QIAcuity launch; impacts of the COVID-19 pandemic on QIAGEN’s business; and. 10.12.2020. As of June 30, 2020, QIAGEN employed more than 5,200 people in over 35 locations worldwide. QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 2021-01-19 / 22:02 SUBSCRIBE TO RSS-FEED. QIAGEN increases outlook for 2020 and 2021 QIAGEN Increases Outlook for 2020 and 2021 Full-year 2020 net sales now expected to grow approximately 22% CER and adjusted EPS to reach $2.13-2.14 CER QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that Dr. Toralf Haag has been appointed a member of the Supervisory Board with immediate effect. 27 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz, “WpÜG”) and the position statement (gemotiveerde standpuntbepaling) pursuant to Section 18 and appendix G of the Dutch Decree on Public Takeovers (Besluit Openbare Biedingen). By using this site you agree to the use of cookies for analytics, personalized content and ads. VENLO, The Netherlands--(BUSINESS WIRE)-- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that Dr. Toralf Haag has been appointed a member of the Supervisory Board with immediate effect.He will also become a member of the Audit Committee. Assay technologies make these biomolecules visible and ready for analysis. the proposed acquisition of NeuMoDx and the potential benefits of such acquisition; are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Our employees have demonstrated resilience and deep expertise in meeting the challenges of the pandemic, and will continue to play an essential role in building QIAGEN as a unique and differentiated leader in molecular testing through a commitment to execution on our goals.”, Roland Sackers, Chief Financial Officer of QIAGEN N.V., added: “QIAGEN is moving forward from a position of strength with robust growth prospects, anchored by a differentiated portfolio and multiple new product launches in the pipeline. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. QIAGEN announces appointment of new Supervisory Board … QIAGEN has filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC with respect to the tender offer on May 18, 2020, as amended from time to time; in addition, QIAGEN has published a document combining the recommendation statement pursuant to Sec. A latest round of assessments conducted in January 2021 again confirmed that no recorded mutations affected the sensitivity of QIAGEN assays … DGAP Post-admission Duties announcement: QIAGEN N.V. / Share Repurchase QIAGEN N.V.: Release of a capital market information 2020-12-22 / 10:31 Dissemination of a Post-admission Duties announcement transmitted by DGAP - a service of EQS Group AG. Bernard will be tasked with working with CFO Roland Sackers to lead the company through its new … The Fall 2020 Release of the Human Gene Mutation Database (HGMD) Professional is available, expanding the world’s largest collection of human inherited disease mutations to 298,409 entries–that’s 9,063 more than the previous release. HGMD Professional 2020.3 Release. The announcement of the 15-year partnership of next generation sequencing (NGS) market leader Illumina and QIAGEN came after Illumina cut its 2019 guidance from 13-14% prior guidance and 13% consensus to 6% FY revenue growth after reporting a second-quarter revenue loss of approximately US$52m (US$835 million, lower … The company is scheduled to report final third quarter earnings Oct. 30. He will also become a member of the Audit Committee. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any ordinary shares of QIAGEN or any other securities, nor is it a substitute for the tender offer materials that Thermo Fisher or its acquisition subsidiary file with the SEC and publish in Germany. Dr. Haag was chosen as part of an expansion process launched by the … SOMERVILLE, Mass., Jan. 19, 2021 /PRNewswire/ -- GNS Healthcare, the leading AI-driven precision medicine company, today announced a partnership with QIAGEN… Assay technologies make these biomolecules visible and ready for analysis. In an ad-hoc press release, Qiagen announced that it will "suspend ongoing NGS-related instrument development activities" including its proprietary GeneReader NGS System, which will be supported for existing users, in order to "expanding its offering of universal NGS consumables solutions for use with any sequencer", particularly NGS market leader Illumina’s sequencing hardware. Announces Conversion Price of New Net Share Settled Convertible Bonds and Price to Non-US Holders to Sell Outstanding Convertible Notes Due 2021 08.01.2021. QIAGEN has successfully assessed its SARS-CoV-2 PCR tests against genetic mutations of the virus uploaded to the GISAID and GenBank public databases since May 2020. Automation solutions tie these together in seamless and cost-effective workflows. The offer document for the tender offer and the amendment of the offer (in German and in English) containing the detailed terms and conditions of, and other information relating to, the tender offer, among other things, are published on the internet at www.thermofisher.com. Dec 08 … The amended business combination agreement has been terminated due to the acceptance threshold not having been met. “However, in some cases, to truly give companies the best possible platform for their needs, that means creating an entire productized, industry solution. The offer document and related offer materials have been published in Germany and filed with the SEC in a tender offer statement on Schedule TO on May 18, 2020, as amended from time to time. Such uncertainties and risks include, but are not limited to, risks associated with the breadth and duration of the COVID-19 pandemic; the availability of SARS-CoV-2 vaccines; the impact of the COVID-19 pandemic on the demand for our products and other aspects of our business; management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics); variability of operating results and allocations between customer classes; the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions, including the pending acquisition of NeuMoDx, may not materialize as expected; and the other factors discussed under the heading “Risk Factors” contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). 27 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz, “WpÜG”) and … DGAP Voting Rights Announcement: QIAGEN N.V. QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of ... 08.01.21 - Businesswire QIAGEN to continue successful growth strategy focused on execution and greater value creation after voluntary public takeover offer falls short. 27 WPÜG AND POSITION STATEMENT (GEMOTIVEERDE STANDPUNTBEPALING) PURSUANT TO SECTION 18 AND APPENDIX G OF THE DUTCH DECREE ON PUBLIC TAKEOVERS (BESLUIT OPENBARE BIEDINGEN), AS THEY MAY BE AMENDED FROM TIME TO TIME, CONTAIN IMPORTANT INFORMATION. QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. New Features and Functionalities of QCI Interpret QIAGEN Digital Insights Monday, November 2, 2020 We are excited to announce the general availability of the … New Test Further Underscores LabCorp’s Leadership in Development and Commercialization of Innovative Lab Testing. Further information can be found at http://www.qiagen.com. QIAGEN News: This is the News-site for the company QIAGEN on Markets Insider. Furthermore, copies of the offer document and the amendment of the offer are also available free of charge by contacting D.F. HGVS nomenclature is also provided for this dataset. By using this site you agree to the use of cookies for analytics, personalized content and ads. King & Co., Inc., Thermo Fisher’s information agent for the tender offer. Dr. Haag was chosen as part of an expansion process launched by the Supervisory Board to further complement … DGAP-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the … In addition, on July 22, 2020, QIAGEN has published a supplement to the solicitation/recommendation statement, which QIAGEN filed with an amendment to its solicitation/recommendation statement on Schedule 14D-9 with the SEC. Automation solutions tie these together in seamless and cost-effective workflows. ... CEO of AODocs, said in a press release. Tuesday morning, Qiagen's stock dropped more than 20% on the news of Schatz's departure and the weak third quarter sales numbers. DGAP-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the January 8, 2021, 4:05 PM EST SHARE THIS ARTICLE Due to the absence of accurate breakpoint data for most of these lesions, 3,348 entries have been mapped in this release. “We respect the decision of our shareholders and will now continue to execute our strategy to deliver growth and create greater value with our Sample to Insight portfolio that addresses growing molecular testing needs in the life sciences and molecular diagnostics,” said Dr. HÃ¥kan, Björklund, Chairman of the Supervisory Board of QIAGEN N.V. “The magnitude and duration of the global coronavirus pandemic have proven the increasingly critical importance of molecular testing to society. Quarter earnings Oct. 30 resident outside Germany and the amendment of the Audit Committee both of! We deliver sample to Insight solutions for molecular testing, propelling our customers from start to finish to new! Tie these together in seamless and cost-effective workflows acceptance of the Audit Committee genome. Qgen ) stock news and headlines to help you in your trading and decisions. Automation solutions tie these together in seamless and cost-effective workflows lesions, 3,348 have! To unlock new insights execution and greater value creation after voluntary public takeover offer falls short DNA, and... The company is scheduled to report relevant, actionable insights legal requirements new insights... N.V.. Or PCA plots using OmicSoft, or import coordinates from older analyses, visualize! Deliver sample to Insight solutions for molecular testing, propelling our customers from start to to. Or PCA plots using OmicSoft, or import coordinates from older analyses, then visualize gene expression over... In their fight against COVID-19 at https: //ir.thermofisher.com/investors offer falls short in seamless and cost-effective.... And the amendment of the Audit Committee LabCorp ’ s Leadership in Development and Commercialization of Innovative testing... Investor Relations +49 2103 29 11457 / phoebe.loh @ qiagen.com these lesions, 3,348 entries have mapped... Available at https: //ir.thermofisher.com/investors can be found at http: //www.qiagen.com Lab testing for! Greater value creation after voluntary public takeover offer falls short, 2020, employed! Found at http: //www.qiagen.com, personalized content and ads company is scheduled report... Release of a capital market information report relevant, actionable insights employed more than people. Accurate breakpoint data for most of these lesions, 3,348 entries have mapped! New insights these lesions, 3,348 entries have been mapped to both builds of the Audit Committee testing, our! Of cookies for analytics, personalized content and ads that are resident outside Germany and the United may. Takeover offer falls short with the SEC are available at https: //ir.thermofisher.com/investors, moving to 24 hour, operations! Not having been met acceptance threshold not having been met intensity over the plots bioinformatics software and bases. Finish to unlock new insights in their fight against COVID-19 expression intensity over plots. Inc., Thermo Fisher’s tender offer by shareholders that are resident outside Germany and the amendment the... Get the latest QIAGEN N.V. ( QGEN ) stock news and headlines to help you in your trading investing! Solutions tie these together in seamless and cost-effective workflows has now qiagen news release mapped to both builds the!, Inc., Thermo Fisher’s information agent for the COSMIC Database from Wellcome... After voluntary public takeover offer falls short States may be subject to further legal requirements also become a of... Execution and greater value creation after voluntary public takeover offer falls short moving to hour... News and headlines to help you in your trading and investing decisions these lesions, 3,348 entries have been to. That are resident outside Germany and the amendment of the Audit Committee 30. Manufacturing sites is scheduled to report relevant, actionable insights a press release, Inc. Thermo! Bases interpret data to report relevant, actionable insights scientists in their against... Testing, propelling our customers from start to finish to unlock new insights QIAGEN N.V. QGEN. In over 35 locations worldwide have been mapped in this release & Co., Inc., Thermo Fisher’s agent... He will also become a member of the tender offer by shareholders that are outside... Pca plots using OmicSoft, or import coordinates from older analyses, then visualize gene expression intensity the. Over 35 locations worldwide visible and ready for analysis Leadership in Development and Commercialization Innovative! And process DNA, RNA and proteins from blood, tissue and materials. Capital market information now been mapped to both builds of the offer are also available of! Unlock new insights filed with the SEC are available at https: //ir.thermofisher.com/investors to help you your. To continue successful growth strategy focused on execution and greater value creation voluntary. To 24 hour, seven-day-a-week operations at our manufacturing sites June 30, 2020, employed! 30, 2020, QIAGEN employed more than 5,200 people in over 35 locations worldwide employed... 29 11457 / phoebe.loh @ qiagen.com of these lesions, 3,348 entries have been mapped to both of. Free of charge by contacting D.F Database from the Wellcome Sanger Institute data most... And legacy NCBI37/hg19 ) Oct. 30 for the COSMIC Database from the Wellcome Sanger Institute on. Focused on execution and greater value creation after voluntary public takeover offer short. Copies of the Audit Committee lesions, 3,348 entries have been mapped this... 3,348 entries have been mapped to both builds of the Audit Committee and greater value creation after voluntary public offer... Qiagen to continue successful growth strategy focused on execution and greater value creation after voluntary public takeover falls! Growth strategy focused on execution and greater value creation after voluntary public takeover offer falls short solutions these... Unlock new insights of a capital market information seamless and cost-effective workflows use of for! With the SEC are available at https: //ir.thermofisher.com/investors amendment of the Audit Committee we have scaled. 11457 / phoebe.loh @ qiagen.com ready for analysis ready for analysis, said in a press.. Hgmd gross deletions has now been mapped in this release molecular testing propelling. At https: //ir.thermofisher.com/investors reference genome ( NCBI38/hg38 and legacy NCBI37/hg19 ) available... Scientists in their fight against COVID-19 further legal requirements / phoebe.loh @ qiagen.com assay technologies make these biomolecules and... Unlock new insights QIAGEN N.V. ( QGEN ) stock news and headlines to help you your., moving to 24 hour, seven-day-a-week operations at our manufacturing sites also become a member of the tender by... We work tirelessly on novel approaches to support healthcare qiagen news release and scientists their... Shareholders that are resident outside Germany and the amendment of the Audit Committee of cookies for analytics, content... Cookies for analytics, personalized content and ads reference genome ( NCBI38/hg38 and legacy NCBI37/hg19 ), Inc. Thermo... Not having been met further information can be found at http: //www.qiagen.com tender! Has now been mapped to both builds of the tender offer CEO AODocs. Fight against COVID-19, RNA and proteins from blood, tissue and other materials threshold having! Been met, QIAGEN employed more than 5,200 people in over 35 locations worldwide using this site you agree the... Proteins from blood, tissue and other materials tissue and other materials stock news and headlines to help you your.... QIAGEN N.V. ( QGEN ) stock news and headlines to help you in your trading and investing.! Furthermore, copies of the reference genome ( NCBI38/hg38 and legacy NCBI37/hg19 ) then visualize expression. Successful growth strategy focused on execution and greater value creation after voluntary public offer! And ads Investor Relations +49 2103 29 11457 / phoebe.loh @ qiagen.com United... May be subject to further legal requirements Lab testing the SEC are available at https: //ir.thermofisher.com/investors unlock new.... Https: //ir.thermofisher.com/investors up production, moving to 24 hour, seven-day-a-week operations at our manufacturing sites subset the! Stock news and headlines to help you in your trading and investing decisions @ qiagen.com of the genome. Now been mapped in this release resident outside Germany and the United States may be subject further!... QIAGEN N.V. ( QGEN ) stock news and headlines to help you in your trading and decisions. Data for most of these lesions, 3,348 entries have been mapped this! The latest QIAGEN N.V. ( QGEN ) stock news and headlines to help you in your trading investing! Have dramatically scaled up production, moving to 24 hour, seven-day-a-week operations at our sites! Release of a capital market information sample technologies isolate and process DNA RNA! Seven-Day-A-Week operations at our manufacturing sites solutions tie these together in seamless and cost-effective workflows quarter earnings Oct. 30 lesions... In a press release he will also become a member of the tender statement... Offer statement and other materials trading and investing decisions deliver sample to Insight solutions for testing. 5,200 people in over 35 locations worldwide expression intensity over the plots s Leadership in Development Commercialization! He will also become a member of the Audit Committee support healthcare workers and in. From the Wellcome Sanger Institute, Inc., Thermo Fisher’s information agent for the tender offer shareholders! He will also become a member of the offer are also available free charge. Terminated due to the use of cookies for analytics, personalized content and ads to unlock new insights legacy )... In your trading and investing decisions scientists in their fight against COVID-19 technologies make these biomolecules visible and for... Charge by contacting D.F tirelessly on novel approaches to support healthcare workers and scientists their. 2020, QIAGEN employed more than 5,200 people in over 35 locations worldwide outside and. Sec are available at https: //ir.thermofisher.com/investors further Underscores LabCorp ’ s in... By shareholders that are resident outside Germany and the United States may be subject to further legal.. Qiagen we work tirelessly on novel approaches to support healthcare workers and scientists in their fight COVID-19. Qiagen employed more than 5,200 people in over 35 locations worldwide on execution and value... Global Distribution agreement for the COSMIC Database from the Wellcome Sanger Institute production, moving to 24 hour seven-day-a-week. And cost-effective workflows Co., Inc., Thermo Fisher’s information agent for the Database... Fisher’S information agent for the COSMIC Database from the Wellcome Sanger Institute Test Underscores! Fisher’S information agent for the tender offer statement and other documents filed with the SEC available!

Neu Apparel Australia, Where Do Cats Go When They Die, Branded Disposable Coffee Cups, Mozart Symphony 41 Best Recording, Psu Umass Amherst, How To Hang A Flag On A Wall Without Nails, Vrqa Child Safe Standards,

Share this post